Effects of traditional Chinese medicine formula Le-Cao-Shi on hepatitis B: In vivo and in vitro studies
| Autor: | Shi-Jun Yue, Min Chen, Meng-Qi Zhang, Qing Zhao, Ren Xia, Yue-Wei Guo, Chang-Yun Wang, Kai-Xian Chen, Chang-Lun Shao |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
HBsAg
Cell Survival Traditional Chinese medicine Pharmacology medicine.disease_cause Antiviral Agents Hepatitis B Virus Duck 03 medical and health sciences 0302 clinical medicine In vivo Cell Line Tumor Drug Discovery medicine Animals Humans Hepatitis B e Antigens Medicine Chinese Traditional 030304 developmental biology Hepatitis B virus Hepatitis B in China 0303 health sciences Hepatitis B Surface Antigens integumentary system business.industry virus diseases Hepatitis B medicine.disease digestive system diseases In vitro Ducks HBeAg Liver 030220 oncology & carcinogenesis Hepatitis Viral Animal DNA Viral business Drugs Chinese Herbal |
| Zdroj: | Journal of ethnopharmacology. 244 |
| ISSN: | 1872-7573 |
| Popis: | Ethnopharmacological relevance Formula Le-Cao-Shi (LCS) is a traditional Chinese medicine (TCM), which has long been used as a folk remedy against hepatitis B in China. The present study was conducted to evaluate the anti-hepatitis B effects of aqueous extract of LCS in vivo and in vitro. Materials and method we investigated the anti-HBV effects of LCS in vivo and in vitro with duck hepatitis B model and HepG2.2.15 cell line model, respectively. The serologic and cellular biomarkers and the histopathological changes were examined. Results By a duck hepatitis B model, the extract of LCS was found to restrain the expressions of duck hepatitis B surface antigen (DHBsAg), hepatitis B e antigen (DHBeAg), and HBV-DNA (DHBV-DNA). Moreover, LCS could decrease the levels of aspartate and alanine aminotransferases (AST and ALT) and ameliorate duck liver histological lesions. Correspondingly, in a HepG2.2.15 cellular model, LCS could also significantly inhibit the secretions of HBsAg and HBeAg. Conclusion LCS exerted potent anti-hepatitis effects against the infection of HBV. The above results demonstrated the first-hand experimental evidences for the anti-hepatitis B efficiency of LCS. Our study provides a basis for further exploration and development of this promising compound prescription to treat hepatitis B disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect